You are here

herpes zoster

In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects

Yahoo

Sat, 02/25/17 - 02:00 pm

varicella zoster

Merck: High Upside Expected From Vaccine

Seeking Alpha

Wed, 04/4/12 - 08:32 am

Inhibitex: Recent Price Action Sees Pressure To Cover Mounting

Seeking Alpha

Sun, 10/9/11 - 03:59 pm

Mylan now selling generic version of Novartis' herpes drug Famvir

Yahoo/AP

Wed, 04/20/11 - 12:01 pm

Four Biotechs to Watch Early This Week

Seeking Alpha

Sun, 03/6/11 - 12:35 pm

ImmunoCellular Therapeutics

glioblastoma multiforme

Jazz Pharmaceuticals

Repros Therapeutics